Philadelphia positive acute lymphoblastic leukaemia of childhood
Authors:
- 4 July 2005
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 130 (4) , 489-500
Abstract
Summary: On current chemotherapeutic regimens, children with Philadelphia positive acute lymphoblastic leukaemia show a heterogeneous response to treatment. A few respond quickly to treatment and achieve long‐term remission. Some fail to achieve remission after induction and the majority respond slowly to treatment. Relapse on treatment is common and remission is sustained in a proportion of cases only after allogeneic stem cell transplantation (allo‐SCT). The use of imatinib along with conventional cytoreductive therapy, prior to allo‐SCT appears to be the most promising strategy. The future lies in the molecular evaluation of response to treatment and combination targeted chemotherapy.Keywords
This publication has 114 references indexed in Scilit:
- Induction of BCR-ABL–specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cellsBlood, 2005
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- Translational regulation by the p210 BCR/ABL oncoproteinOncogene, 2004
- Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)Leukemia, 2003
- The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylateBlood, 2003
- In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: A report of the Dutch and German Leukemia Study GroupsMedical and Pediatric Oncology, 2002
- Modeling Philadelphia chromosome positive leukemiasOncogene, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic ActivityJournal of Experimental Medicine, 1999